Background Patients with multiple actinic keratoses (AKs) should be treated with field-directed therapy. Such treat-
Introduction
Actinic keratosis (AK) is a common sun-induced lesion occurring in the elderly. Its prevalence ranges between 6% and 25% in European adults over 40 years of age. 1, 2 In Italy, 1.4% of the population self-reported a diagnosis of AK anytime in the life course 3 ; however, such figure possibly underestimates the real prevalence of the disease, as it has been noted elsewhere. 4 Whereas AK may have a self-limiting behaviour, its potential for cancer progression has been largely demonstrated [5] [6] [7] [8] [9] [10] especially for patients with multiple lesions and field cancerization. 11 Therefore, AK often requires repeated treatments and may cause significant morbidity.
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Patients with multiple AKs should be treated with field-directed therapy. However, such treatments challenge patients' adherence and potentially hamper real-life effectiveness due to side effects, out-of-pocket costs, length of treatment and severity of local skin reactions (LSRs). 12, 13 Previous evidence obtained in other chronic conditions has shown that effective physician-patient communication (PPC) may buffer therapy-related distress, thus improving quality of life, treatment satisfaction and adherence.
14 Such outcomes might be particularly important for patients with multiple AKs receiving field-directed topical therapies because, despite the episodic nature of the physician-patient interaction, AK is a chronic disease often requiring multiple retreatments. 15 However, most studies on medication adherence and PPC have been conducted in chronic diseases requiring lifelong monitoring and prolonged interaction with the healthcare professional. In such context, trust is mutually achieved through repeated interactions and the reciprocal experience of reliability, empathy, trustworthiness, agreeability, respect and time consistency. [16] [17] [18] For this reason, results from such studies are not generalizable to the short-term, episodic interactions typical of AK management. We sought to evaluate the interplay between PPC, LSR intensity (safety) and lesion clearance rates (effectiveness) on treatment satisfaction, quality of life and treatment adherence among patients with multiple actinic keratoses receiving topical field-directed therapies.
Methods

Study sample
In this observational, multicentre, longitudinal, cohort study, we enrolled a consecutive sample of adult patients with discrete, clinically detectable, visible, multiple (three or more lesions in a 25 cm 2 area), Grade I/II AKs for whom the attending dermatologist has prescribed a treatment course with a topical field-directed therapy. The research has taken place from July through December 2015. At study onset, ingenol mebutate (IMB), imiquimod 5% (IMQ) and diclofenac 3% in hyaluronic acid (DHA) were available as field-directed topical therapies in Italy. IMB application entails a short treatment course (2-3 days); IMQ requires daily application for 4 weeks; DHA requires 90 days of therapy. Consequently, the three drugs show different LSR time course. IMB-related LSRs have a sharp peak at 4-8 days, whereas DHA and IMQ produce a smoother LSR trajectory over the treatment period.
We excluded patients treated with photodynamic therapy (PDT) as PDT is administered during an outpatient medical encounter or a day-surgery hospitalization by the medical staff. Additionally, we excluded patients undergoing any major surgery or major clinical events in the month prior to enrolment; further, we excluded patients receiving fielddirected therapies in the 3 months prior to enrolment and those with basal cell carcinoma or squamous cell carcinomas in the treated areas.
All patients joining the study signed an informed consent form. Thirty-five dermatology outpatient clinics in Italy joined the AK-TRAIN study group (Appendix 1). The study was approved by the IRB at each participating centre.
Design and procedures
During the first visit, a dermatologist determined study eligibility and filled in a standardized clinical form for each enrolled patient. Patients received instructions on treatment self-administration. In order to characterize LSR pattern for all drugs, patients were advised to return to the clinic after 8 days for the first follow-up visit (T1) and 25-30 days after therapy initiation for the second follow-up visit (T2).
Patients answered a self-administered questionnaire at the end of each medical visit in a quiet room. During the follow-up, dermatologists recorded local skin reactions (LSRs) and their treatment and AK clearance rates.
It is important to notice that the study was not designed to either compare clearance rates, LSR or patient-reported outcomes across different topical treatments. Physicians' prescription choices followed clinical judgment and were not regulated in the protocol, a condition generating indication bias in head-to-head treatment comparisons. Furthermore, our short follow-up time cannot capture the full spectra of clearance rates, LSR and patient-reported outcomes occurring among patients treated with IMQ and DHA, two drugs requiring a longer treatment course compared to IMB. Including different therapies in the study was not meant to perform any treatment comparison but to allow sufficient variations in key predictors and confounders (e.g. LRS pattern and intensity, clearance rate) to test our main hypotheses.
Measures
Outcomes Treatment satisfaction Treatment satisfaction was assessed with the 11-item Treatment Satisfaction Questionnaire on Medications version 2 (TSQM-V2 19 ). Scores range from 0 to 100 and denote patients' satisfaction concerning treatment effectiveness (TSQM-EFF), side effects (TSQM-SE) and convenience (TSQM-CONV).
Quality of life (QOL) We adopted the Dermatology Life Quality Index (DLQI 20 ) and the Actinic Keratosis Quality of Life Questionnaire (AKQOL 21 ). The DLQI is a 10-item questionnaire addressing distress over symptoms and feeling, daily activities, leisure, vocational activity, personal relationship and treatment. The overall score ranges from 0 to 30, with higher score indicating greater QOL disruption. The AKQOL is a 9-item scale evaluating AK-related impact on patient's QOL. Total score ranges from 0 to 27, with higher score indicating greater QOL disruption.
Adherence There is no established adherence scale for patients with AK. Based on interviews to expert dermatologists, we developed several items tapping aspects of dosing frequency, treatment persistence and application modality with 12 questions (Appendix 2). To reduce recall bias, we evaluated adherence considering compliance to the dosing regimen for each drug in the week preceding the interview. Each item was given 1 point when patient's response suggested non-adherence based on drug-specific application schedules, dosing and modality. Points were summed up in a general score indicating increasing adherence difficulties.
Predictors
Physician-patient communication To our best knowledge, there was no validated scale assessing PPC in dermatology. For this reason, we developed a new scale (10 items, Appendix 2) based on a roundtable discussion with expert dermatologists and items adapted from existing scales. We selected two major dimensions of PPC: clarity and emotional support. For both scales, ratings occurred along a 5-point Likert scale (1 = not at all; 5 = yes, fully).
Lesion count At each visit, all AK lesions in the treated area have been counted and classified according to Olsen grading system. 22 We defined clearance rate as follows:
(1) (AK B -AK F )/AK B, where AKB represents baseline count, whereas AKF represents follow-up count.
Local skin reactions Local skin reactions included erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration graded on a scale from 0 (no reaction) to 4 (severe reaction). The composite LSR score is the sum of the six individual scores.
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Covariates and confounders We recorded the number, localization and clinical grading of treated AK lesions, comorbidities, concurrent medications, skin phototype, photoaging, AK risk factors (occupational exposures, tobacco smoke, sun burns, immunosuppression), evidence of field cancerization, other skin tumours, previous treatments for AK, time since AK diagnosis and time since the last treatment. Additionally, patients' questionnaire included the PHQ4 for the screening of anxiety and depression disorders, 24 education, marital status, employment status and treatment-related pain. We computed alcohol unit daily intake and pack-years of smoking from questionnaires responses based on standard formulas for epidemiologic studies. Additionally, we computed cumulative years of exposure to occupational risk factors by summing the attendance time for each occupation at risk.
Statistical methods
Sample characteristics have been summarized with mean and standard deviation or absolute and relative frequency where appropriate. The trajectories of LSR, treatment satisfaction and QOL along the follow-up have been evaluated with generalized estimating equations accounting for the intercorrelations of observations within subjects. Differences in the shape of treatment satisfaction and QOL trajectories across LSR severity and PPC scores (clarity, emotional support) have been evaluated with the appropriate interaction terms. Correlates of clearance rate have been evaluated with negative binomial regression with robust standard errors and log-link functions to account for overdispersed data. All models have been adjusted for baseline AK count, age, gender, previous history of skin cancer, skin phototype, disease vintage, pack-years of cigarette smoke, alcohol unit daily intake, number of comorbidities, cumulative exposure time to occupational risk factors, education, marital status, mental health, anxiety and depression scores, gastrointestinal disorders, lung diseases, cardiovascular disease and diabetes. Analyses have been performed with SAS 9.4 â .
Results
Sample characteristics
Among 1176 eligible patients, 40 were further excluded because either receiving DNA repair enzymes without any topical field-directed therapy or due to missing responses in all questionnaire items. Hence, there were 1136 valid cases. Of them, 961 had a prescription of IMB and 175 patients received other treatments for AK (i.e. DHA or IMQ). Sample characteristics are summarized in Table 1 .
Predictors
Physician-patient communication Most patients felt very supported (n = 819, 73%; mean communication clarity = 23.2 AE 4.0) and rated dermatologist's explanations very clear (n = 608, 54%; mean emotional support = 16.6 AE 2.7). Correlates of clarity were patient's history of skin cancer (b = 0.81, P < 0.01), PHQ4 anxiety score (b = À0.49, P < 0.01) and baseline AKrelated distress (AKQOL score, b = 0.75, P < 0.01). Correlates of perceived emotional support were PHQ4 depression score (b = À0.39, P < 0.01) and AK-related distress (AKQOL score, b = 0.51, P < 0.01).
Lesion clearance rate At the end of follow-up (T2), there were 0.98 lesions per patient in the treated area. The overall clearance rate at 1 month was 84% (Grade I, 84%; Grade II, 85%). The risk of residual lesions was lower among patients with longer time since first AK diagnosis (RR: 0.95 for each year, P = 0.02), treatment with IMB (RR = 0.56, P < 0.01) and no history of skin cancer (RR: 0.46, P < 0.01); conversely, patients with more comorbidities (RR: 1.30 for each additional disease, P = 0.03) had higher rate of residual lesions.
Local skin reactions The average LSR score was 2.6 AE 1.5 at T1. LSR extending over the treated area at this time point of assessment was reported by dermatologists in 24% of patients. LSR score dropped at 0.9 AE 1.0 at the end of follow-up. Roughly, 37% of patients received any treatment for the LSR in the first 8 days of study and 14% in the remaining follow-up time. Among patients receiving treatment for the LSR at T1, 47% received emollient creams while 53% received topical antibiotics. At T2, 70% of those receiving a treatment for LSR received emollient creams and 29% received antibiotics. Patients treated with IMB had higher LSR score at T1 (IngMeb: 2.7 AE 1.4; other: 1.9 AE 1.3; Cohen's d = 0.57; P < 0.01); the LSR at T2 (25-35 days) was greater for patients treated with DHA or IMQ (IMB: 0.8 AE 0.8; other: 1.5 AE 1.5; Cohen's d = 0.87; P < 0.01). There was a statistically significant interaction indicating a steeper decrease in LSR score among patients treated with IMB (P < 0.01). In the latter group, LSR at T2 was mainly caused by residual erythema.
Outcomes
Treatment satisfaction Treatment satisfaction (effectiveness and convenience scales) increased along the follow-up (Table 2) . However, the improvement in convenience scores was entirely due to patients on IMB (IMB: D pre-post = À4.00; other: D pre-post = À0.25; interaction, P < 0.001).
Communication clarity was associated with higher TSQM scores. This pattern was confirmed after adjustment for potential confounders (Table 2 ). Stronger emotional support was associated with greater satisfaction towards treatment side effects. Neither communication clarity nor emotional support moderated the relationship between LSR score, clearance rate and patients' satisfaction (P for interactions >0.10).
Quality of life Mean baseline DQLI and AKQOL scores were 12.2 AE 2.8 and 17.0 AE 5.3, respectively. There was a statistically significant trend indicating worse DLQI at T1 and improved DLQI at T2. This pattern was stronger for patients treated with IMB (IMB, Χ 2 = 0.02, P = 0.89; time point, Χ 2 = 58.34, P < 0.001; IMB*time point, Χ 2 = 12.13, P < 0.002). Communication clarity and emotional support did not moderate the relationship between LSR score and HRQOL (P for interactions >0.10) and were not associated with DLQI (P > 0.10). Correlates of distress related to patient's skin disease (DQLI score) were PHQ depression score (b = 0.6; P < 0.01), LSR (time-varying covariate, b = 0.5; P < 0.01), and being woman (b = 0.4; P = 0.02), fair phototype (b = 0.4; P = 0.02), alcohol units intake (b = 0.01 per unit increase; P = 0.01) and time since AK diagnosis (b = 0.01 per year; P < 0.01). Furthermore, patients reporting higher emotional support from the dermatologist reported reduced AK-related distress (i.e. smaller AKQOL scores) throughout the study (b = 0.2; P < 0.01). Correlates of AKQOL were older age (b = À0.1; P < 0.01); months since first AK diagnosis (b = 0.01; P < 0.01); number of comorbidities (b = 0.3; P < 0.05); being woman (b = 0.8; P < 0.01); fair phototype (b = 0.8; P < 0.01); history of skin cancer (b = 0.7; P < 0.01); history of cardiovascular disease (b = 0.7; P < 0.01); PHQ4-D score (b = 1.9; P < 0.01); PHQ4-A score (b = 1.3; P < 0.01); LSR score (b = 0.9; P < 0.01); and AK lesion clearance rate at the end of follow-up (b = À0.2; for each 10% increase in rate, P < 0.01).
Treatment adherence Patients on long treatment courses were more likely to report difficulties in adhering to the treatment regimen compared to patients on IMB (Figure 1) . Patients' reported difficulties in following medical instructions (i.e. avoid application within 2 h before bed time, 46%; washing the treated area earlier than 6 hours postapplication, 14%). Patients on long treatment course had higher chance to skip more than 20% of prescribed applications (IMB: n = 50, 5.2%; other treatments: n = 96, 74%; P < 0.01). Communication clarity was associated with increased treatment adherence only among patients on IMB after adjustment for potential confounders (Table 3) .
Discussion
In this longitudinal cohort study, we assessed the interplay between psychological and clinical variables and their contribution to treatment satisfaction, quality of life and self-reported difficulties in treatment adherence. We found that communication clarity during the first medical encounter contributed to patients' satisfaction over the treatment course. This pattern was confirmed after adjustment for potential confounders such as affective mood, LSR and lesion clearance rate. The importance of social support from healthcare providers for improving patients-reported outcomes has been observed in therapeutic areas where repeated interactions concur to the development of therapeutic allegiance. 14, [25] [26] [27] Our results suggest communication clarity even in the setting of short, episodic relationships can affect multiple dimensions of patients' well-being, beyond clinical parameters. The association of patient's assessment of PPC with adherence was less clear. Patients receiving IMB benefited from higher communication clarity by improved adherence. In this group, the effect of communication clarity could completely counterbalance the impact of depressed mood, a well-known risk factor for non-adherence. [28] [29] [30] Conversely, among patients on DHA or IMQ, the experience of LSR, basal AK count and depressed mood played a major role in modulating medication adherence; furthermore, our data suggest that improved communication clarity had a trivial effect on adherence and thus cannot counterbalance such effects among these patients. Such differential association pattern is not surprising. Consistent with findings in different therapeutic areas, our data indicate that the experience and the cognitive appraisal of treatment-related discomfort and effectiveness play a key role in adherence choices. 26, 31 The LSRs experienced by patients on IMB start only few days after the end of their treatment course. Therefore, treatment-related discomfort cannot influence patients' adherence behaviour; on the other hand, those applying other topical medications experience local side effects and AK clearance during their whole treatment period. Therefore, they have sufficient time to incorporate belief around medication safety and efficacy into their decisionmaking process. 31 Differences in patients' self-reported adherence difficulties seem to be mirrored by actual prescription patterns. Patients in our sample received either IMB, IMQ or DHA. IMB was preferentially administered to older men, with higher disease burden (several, recurrent lesions with clinical evidence of photoaging) and greater exposure to occupational risk factors. Even though we could not assess elements of clinical decision-making, this prescription pattern might reflect physicians concerns towards non-adherence to lengthy treatment, 32 especially for patients needing a more aggressive therapeutic approach.
One further important finding of our research is that correlates of patient-reported outcomes (PRO) were not limited to objective dermatology-relevant factors such as lesion density, time since first AK diagnosis, LSR intensity and clearance rate. General patient's health determinants such as life style (i.e. alcohol consumption), comorbidities, affective mood and past exposure to occupational risk factors, explained a large share of variance in PRO. These findings are consistent with the vast evidence collected in several other therapeutic areas. Given the chronic behaviour of AK and the need of repeated treatment courses in the majority of patients with field cancerization, our results question the validity of a treatment model based on short, episodic medical encounters where physician-patient interactions are extremely focused on AK-related aspects rather than the more complex interplay between patients' general health, beliefs and treatments.
Our study has several strengths. First, our large sample size and extensive data collection procedures allowed estimating the effect of several potential antecedents of patient-reported outcomes in dermatology. Hence, we provide a comprehensive picture of modifiable factors and risk markers for poor treatment satisfaction, adherence and HRQOL. Second, we minimized potential information bias by adopting medical reports of clinical information, thus avoiding the well-known inaccuracies of self-reported data for such variables. Third, we conducted the study in several centres in Italy, located in culturally diverse areas, thus reducing the potential for selection bias. Finally, our longitudinal design allows avoiding reverse causality bias. In conclusion, we demonstrated that patient assessment of clinical encounters is associated with patient-reported outcomes and adherence beyond AK-related parameters even in a context of episodic medical interactions. Given the need for repeated treatment course among patients with multiple AKs, our study provides the rationale to test the effectiveness of holistic treatment models typical of chronic disease management.
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